UK researchers found that type 2 diabetes patients with several markers of higher insulin resistance -- such as higher fasting C-peptide, triglycerides and homeostatic assessment model of insulin resistance-2 -- experienced a reduced A1C response to DPP-4 inhibitors at six months, compared with those with less insulin resistance. The findings in Diabetes Care, based on data from 254 diabetes patients not treated with insulin and EMRs of 23,001 patients, also revealed an association between response to DPP-4 inhibitors and higher body mass index and triglyceride levels.
Study links insulin resistance to diabetes patients' DPP-4 inhibitor response
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.